Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Aethlon Medical ( (AEMD) ).
On February 12, 2026, Aethlon Medical reported results for its fiscal third quarter ended December 31, 2025, highlighting operational discipline and ongoing clinical and research progress centered on its Hemopurifier device. The company reaffirmed continued compliance with Nasdaq listing requirements, underscoring stability in its market listing while it advances programs aimed at treating cancer and severe infectious diseases.
Clinically, Cohort 2 enrollment and treatment in an Australian oncology trial remained active, following Cohort 1 data that indicated favorable trends in extracellular vesicles and immune cell measures alongside acceptable safety and tolerability. Aethlon also advanced preclinical work on its extracellular vesicle research platform, including Long COVID data showing its GNA affinity resin can bind EVs and reduce microRNAs linked to immune dysregulation.
The company continued evaluating Hemopurifier compatibility with Stavro’s simplified SLAMB blood treatment system under a material transfer agreement, which could eventually broaden clinical use in oncology units and infusion centers without dialysis machines or nephrologist oversight. Additional preclinical plans include extending prior evidence of platelet-derived EV removal in healthy plasma to patient samples across diseases such as autoimmune disorders, cardiovascular disease, sepsis and ALS.
From an operational standpoint, Aethlon emphasized cost control, with operating expenses for the nine months ended December 31, 2025 declining 26.9% to about $5.36 million versus the prior-year period, even as clinical and R&D programs advanced. However, quarterly operating expenses rose 13.6% year over year to roughly $2.06 million, driven mainly by higher payroll, leading to an increased operating loss of $2.06 million for the quarter.
As of December 31, 2025, Aethlon held approximately $7.0 million in cash, providing a limited but tangible financial runway as it pursues its oncology and infectious disease strategy. Other income, largely from interest on cash balances, fell to $44,000 in the quarter, modestly offsetting operating losses but highlighting the company’s continued dependence on external capital and successful pipeline execution for long-term sustainability.
The most recent analyst rating on (AEMD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.
Spark’s Take on AEMD Stock
According to Spark, TipRanks’ AI Analyst, AEMD is a Neutral.
The score is held down primarily by very weak financial performance (minimal/zero recent revenue, large losses, and heavy cash burn). Earnings-call execution on cost reductions and early clinical progress provide some offset, but limited cash and dilution/financing risk (warrants) remain notable. Technicals are mixed with short-term improvement but a still-bearish longer-term trend, and valuation is not supportive due to ongoing losses and no dividend.
To see Spark’s full report on AEMD stock, click here.
More about Aethlon Medical
Aethlon Medical, Inc. is a San Diego-based clinical-stage medical device company focused on therapeutic technologies for cancer and life-threatening infectious diseases. Its lead investigational product, the Hemopurifier, is designed to selectively remove pathogenic targets such as enveloped viruses and tumor-derived extracellular vesicles from circulation, and holds U.S. FDA Breakthrough Device designation in oncology and antiviral indications.
The company’s platform aims to address unmet medical needs in oncology and infectious disease by combining plasma separation, size exclusion and affinity binding, positioning Aethlon within the niche of extracorporeal blood-filtering therapeutics. By advancing this “pipeline within a single device” concept, Aethlon targets complex, immune-related conditions where conventional therapies may be insufficient or poorly tolerated.
Average Trading Volume: 126,491
Technical Sentiment Signal: Sell
Current Market Cap: $2.14M
For detailed information about AEMD stock, go to TipRanks’ Stock Analysis page.